Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 669

The DOI matches its Crossref record.

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1 / 2 (CIMBA)

Open access
Mavaddat, Nasim, Barrowdale, Daniel, Andrulis, Irene L., Domchek, Susan M., Eccles, Diana, Nevanlinna, Heli, Ramus, Susan J., Spurdle, Amanda, Robson, Mark, Sherman, Mark, Mulligan, Anna Marie, Couch, Fergus J., Engel, Christoph, McGuffog, Lesley, Healey, Sue, Sinilnikova, Olga M., Southey, Melissa C., Terry, Mary Beth, Goldgar, David, O'Malley, Frances, John, Esther M., Janavicius, Ramunas, Tihomirova, Laima, Hansen, Thomas V. O., Nielsen, Finn C., Osorio, Ana, Stavropoulou, Alexandra, Benítez, Javier, Manoukian, Siranoush, Peissel, Bernard, Barile, Monica, Volorio, Sara, Pasini, Barbara, Dolcetti, Riccardo, Putignano, Anna Laura, Ottini, Laura, Radice, Paolo, Hamann, Ute, Rashid, Muhammad U., Hogervorst, Frans B., Kriege, Mieke, van der Luijt, Rob B., Peock, Susan, Frost, Debra, Evans, D. Gareth, Brewer, Carole, Walker, Lisa, Rogers, Mark T., Side, Lucy E., Houghton, Catherine, Weaver, JoEllen, Godwin, Andrew K., Schmutzler, Rita K., Wappenschmidt, Barbara, Meindl, Alfons, Kast, Karin, Arnold, Norbert, Niederacher, Dieter, Sutter, Christian, Deissler, Helmut, Gadzicki, Doroteha, Preisler-Adams, Sabine, Varon-Mateeva, Raymonda, Schönbuchner, Ines, Gevensleben, Heidrun, Stoppa-Lyonnet, Dominique, Belotti, Muriel, Barjhoux, Laure, Isaacs, Claudine, Peshkin, Beth N., Caldes, Trinidad, de la Hoya, Miguel, Cañadas, Carmen, Heikkinen, Tuomas, Heikkilä, Päivi, Aittomäki, Kristiina, Blanco, Ignacio, Lazaro, Conxi, Brunet, Joan, Agnarsson, Bjarni A., Arason, Adalgeir, Barkardottir, Rosa B., Dumont, Martine, Simard, Jacques, Montagna, Marco, Agata, Simona, D'Andrea, Emma, Yan, Max, Fox, Stephen, Rebbeck, Timothy R., Rubinstein, Wendy, Tung, Nadine, Garber, Judy E., Wang, Xianshu, Fredericksen, Zachary, Pankratz, Vernon S., Lindor, Noralane M., Szabo, Csilla, Offit, Kenneth, Sakr, Rita, Gaudet, Mia M., Singer, Christian F., Tea, Muy-Kheng, Rappaport, Christine, Mai, Phuong L., Greene, Mark H., Sokolenko, Anna, Imyanitov, Evgeny, Toland, Amanda Ewart, Senter, Leigha, Sweet, Kevin, Thomassen, Mads, Gerdes, Anne-Marie, Kruse, Torben, Caligo, Maria, Aretini, Paolo, Rantala, Johanna, von Wachenfeld, Anna, Henriksson, Karin, Steele, Linda, Neuhausen, Susan L., Nussbaum, Robert, Beattie, Mary, Odunsi, Kunle, Sucheston, Lara, Gayther, Simon A., Nathanson, Kate, Gross, Jenny, Walsh, Christine, Karlan, Beth, Chenevix-Trench, Georgia, Easton, Douglas F., Antoniou, Antonis C.·2012·Cancer Epidemiology, Biomarkers & Prevention

Abstract

Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further tumor characterization. Methods: We used data from 4,325 BRCA1 and 2,568 BRCA2 mutation carriers to analyze the pathology of invasive breast, ovarian, and contralateral breast cancers. Results: There was strong evidence that the proportion of estrogen receptor (ER)-negative breast tumors decreased with age at diagnosis among BRCA1 (P-trend = 1.2 × 10−5), but increased with age at diagnosis among BRCA2, carriers (P-trend = 6.8 × 10−6). The proportion of triple-negative tumors decreased with age at diagnosis in BRCA1 carriers but increased with age at diagnosis of BRCA2 carriers. In both BRCA1 and BRCA2 carriers, ER-negative tumors were of higher histologic grade than ER-positive tumors (grade 3 vs. grade 1; P = 1.2 × 10−13 for BRCA1 and P = 0.001 for BRCA2). ER and progesterone receptor (PR) expression were independently associated with mutation carrier status [ER-positive odds ratio (OR) for BRCA2 = 9.4, 95% CI: 7.0–12.6 and PR-positive OR = 1.7, 95% CI: 1.3–2.3, under joint analysis]. Lobular tumors were more likely to be BRCA2-related (OR for BRCA2 = 3.3, 95% CI: 2.4–4.4; P = 4.4 × 10−14), and medullary tumors BRCA1-related (OR for BRCA2 = 0.25, 95% CI: 0.18–0.35; P = 2.3 × 10−15). ER-status of the first breast cancer was predictive of ER-status of asynchronous contralateral breast cancer (P = 0.0004 for BRCA1; P = 0.002 for BRCA2). There were no significant differences in ovarian cancer morphology between BRCA1 and BRCA2 carriers (serous: 67%; mucinous: 1%; endometrioid: 12%; clear-cell: 2%). Conclusions/Impact: Pathologic characteristics of BRCA1 and BRCA2 tumors may be useful for improving risk-prediction algorithms and informing clinical strategies for screening and prophylaxis. Cancer Epidemiol Biomarkers Prev; 21(1); 134–47. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-11-0775

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 669

Metadata

Authors
Mavaddat, N., Barrowdale, D., Andrulis, I. L., Domchek, S. M., Eccles, D., Nevanlinna, H., Ramus, S. J., Spurdle, A., Robson, M., Sherman, M., Mulligan, A. M., Couch, F. J., Engel, C., McGuffog, L., Healey, S., Sinilnikova, O. M., Southey, M. C., Terry, M. B., Goldgar, D., O'Malley, F., John, E. M., Janavicius, R., Tihomirova, L., Hansen, T. V. O., Nielsen, F. C., Osorio, A., Stavropoulou, A., Benítez, J., Manoukian, S., Peissel, B., Barile, M., Volorio, S., Pasini, B., Dolcetti, R., Putignano, A. L., Ottini, L., Radice, P., Hamann, U., Rashid, M. U., Hogervorst, F. B., Kriege, M., van der Luijt, R. B., Peock, S., Frost, D., Evans, D. G., Brewer, C., Walker, L., Rogers, M. T., Side, L. E., Houghton, C., Weaver, J., Godwin, A. K., Schmutzler, R. K., Wappenschmidt, B., Meindl, A., Kast, K., Arnold, N., Niederacher, D., Sutter, C., Deissler, H., Gadzicki, D., Preisler-Adams, S., Varon-Mateeva, R., Schönbuchner, I., Gevensleben, H., Stoppa-Lyonnet, D., Belotti, M., Barjhoux, L., Isaacs, C., Peshkin, B. N., Caldes, T., de la Hoya, M., Cañadas, C., Heikkinen, T., Heikkilä, P., Aittomäki, K., Blanco, I., Lazaro, C., Brunet, J., Agnarsson, B. A., Arason, A., Barkardottir, R. B., Dumont, M., Simard, J., Montagna, M., Agata, S., D'Andrea, E., Yan, M., Fox, S., Rebbeck, T. R., Rubinstein, W., Tung, N., Garber, J. E., Wang, X., Fredericksen, Z., Pankratz, V. S., Lindor, N. M., Szabo, C., Offit, K., Sakr, R., Gaudet, M. M., Singer, C. F., Tea, M.-K., Rappaport, C., Mai, P. L., Greene, M. H., Sokolenko, A., Imyanitov, E., Toland, A. E., Senter, L., Sweet, K., Thomassen, M., Gerdes, A.-M., Kruse, T., Caligo, M., Aretini, P., Rantala, J., von Wachenfeld, A., Henriksson, K., Steele, L., Neuhausen, S. L., Nussbaum, R., Beattie, M., Odunsi, K., Sucheston, L., Gayther, S. A., Nathanson, K., Gross, J., Walsh, C., Karlan, B., Chenevix-Trench, G., Easton, D. F., & Antoniou, A. C.
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2012-01-01
Volume
21
Issue
1
Pages
134-147
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
OpenAlex
W2138733479
Cited by
669
References
0
FWCI
18.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1 / 2 (CIMBA). https://app.cochat.ai/papers/10.1158/1055-9965.epi-11-0775
The paper
Mavaddat, N., Barrowdale, D., Andrulis, I. L., Domchek, S. M., Eccles, D., Nevanlinna, H., Ramus, S. J., Spurdle, A., Robson, M., Sherman, M., Mulligan, A. M., Couch, F. J., Engel, C., McGuffog, L., Healey, S., Sinilnikova, O. M., Southey, M. C., Terry, M. B., Goldgar, D., . . . Antoniou, A. C. (2012). Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1 / 2 (CIMBA). Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-11-0775

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.